Related Experiment Video
Updated: May 23, 2025
11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
22.2K
Carbidopa: beyond Parkinson's disease
Abhishek Lenka1, Steven Vernino2
1Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA. abhishek.lenka@utsouthwestern.edu.
Summary
Carbidopa, beyond Parkinson's disease, shows promise for autonomic disorders like familial dysautonomia and POTS. It effectively manages nausea and sympathetic hyperactivity with a favorable safety profile.
Area of Science:
- Pharmacology
- Neurology
- Internal Medicine
Background:
- Carbidopa is primarily known for its role in Parkinson's disease management.
- Autonomic disorders present complex challenges in patient care.
- Understanding novel therapeutic applications is crucial for improving patient outcomes.
Purpose of the Study:
- To review the pharmacology and real-world applications of carbidopa.
- To explore carbidopa's utility in managing autonomic disorders beyond Parkinson's disease.
Main Methods:
- A comprehensive literature search was performed on PubMed.
- Keywords used included "Carbidopa," "MK-486," and "L-alpha-methyldopa hydrazine."
- Articles were selected for review in January 2025.
Main Results:
- Carbidopa demonstrated efficacy in treating nausea and sympathetic hyperactivity in familial dysautonomia, hyperadrenergic POTS, and afferent baroreflex failure.
- High doses (up to 600 mg/day) were generally well-tolerated in clinical trials for familial dysautonomia.
- Pre-clinical data suggest carbidopa may inhibit T-cell activation and have potential in cytokine release syndrome.
Conclusions:
- Carbidopa exhibits a favorable safety profile for autonomic disorder management.
- Limited evidence suggests carbidopa's utility in treating nausea and sympathetic hyperactivity symptoms.
- Further large-scale studies are needed to confirm carbidopa's therapeutic role in these conditions.
Related Concept Videos
01:24Parkinson's Disease: Treatment
178
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
178
01:15Parkinson's Disease: Overview
415
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
415
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
663
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
663
01:26Cholinergic Antagonists: Therapeutic Uses
699
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
699
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
232
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
232
01:22Alzheimer's Disease: Treatment
142
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
142